{"id":"NCT01313689","sponsor":"Novartis Pharmaceuticals","briefTitle":"Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia","officialTitle":"An Open Label, Multicenter Study Investigating the Safety and Efficacy of Ofatumumab Therapy Versus Physicians' Choice in Patients With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukaemia (CLL)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04-14","primaryCompletion":"2014-03-18","completion":"2017-04-24","firstPosted":"2011-03-14","resultsPosted":"2014-11-24","lastUpdate":"2018-11-08"},"enrollment":122,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Leukaemia"],"interventions":[{"type":"DRUG","name":"Ofatumumab","otherNames":[]},{"type":"DRUG","name":"Physicians' Choice","otherNames":[]}],"arms":[{"label":"Ofatumumab","type":"EXPERIMENTAL"},{"label":"Physicians' Choice","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to confirm the clinical benefit observed in the pivotal registration study, Hx-CD20-406. The Committee for Medicinal Products for Human Use (CHMP) required that a randomized study be conducted in CLL patients with bulky fludarabine-refractory disease as a specific obligation for grant of conditional approval for ARZERRAâ„¢ in the European Union (EU). This study compared ofatumumab with the physicians' choice of therapy.","primaryOutcome":{"measure":"Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC)","timeFrame":"From the randomization date up to 60 months post the randomization date.","effectByArm":[{"arm":"Any Ofatumumab (OFA)","deltaMin":5.36,"sd":null},{"arm":"Physician's Choice (PC)","deltaMin":3.61,"sd":null},{"arm":"Ofatumumab Extended (OFA Ext)","deltaMin":10.05,"sd":null},{"arm":"Ofatumumab Observation (OFA Observ.)","deltaMin":7.16,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2677"},{"comp":"OG002 vs OG003","p":"0.0837"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":12},"locations":{"siteCount":80,"countries":["Austria","Belgium","Bulgaria","Czechia","France","Germany","Hungary","Ireland","Israel","Italy","Poland","Russia","Singapore","Slovakia","Sweden","Ukraine","United Kingdom"]},"refs":{"pmids":["26784000"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":43,"n":78},"commonTop":["Neutropenia","Cough","Nausea","Pyrexia","Thrombocytopenia"]}}